Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-100 vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of pain in opioid-tolerant patients requiring around-the-clock opioid analgesia for severe chronic pain,Anesthesia (adjunct to general or regional anesthesia),Procedural sedation,Patient-controlled analgesia (PCA),Breakthrough pain management (off-label use)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 2–4 hours in adults; prolonged in elderly, hepatic impairment, or continuous infusion (due to redistribution).
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via CYP3A4, with minor contribution from CYP3A5. Major metabolites: norfentanyl (inactive), despropionylfentanyl. Approximately 10-25% excreted unchanged in urine.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic metabolism to inactive metabolites (norfentanyl, etc.); ~75% excreted in urine as metabolites, ~9% in feces, <10% unchanged in urine.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~80–85% bound, primarily to albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3–8 L/kg (large Vd indicates extensive tissue distribution, especially to fat and muscle).
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: <40% (first-pass metabolism); Buccal: ~50%; Intranasal: 50–90%; Transdermal: ~30–60% (steady state).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-50 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: reduce dose by 50-75% and extend dosing interval; GFR <10 m L/min: use with caution, consider alternative therapy; not removed by hemodialysis.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative; monitor for respiratory depression.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Intravenous: 0.5-2 mcg/kg/dose every 2-4 hours; transmucosal: 5-15 mcg/kg for procedural analgesia; transdermal patch: not recommended in children <2 years; in older children, use lowest effective dose based on body weight and opioid tolerance.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at 25-50% of adult dose; titrate slowly; avoid transdermal patch in opioid-naive elderly; monitor for delirium and respiratory depression; prefer intravenous or buccal routes with careful observation.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of respiratory depression, which may be fatal, especially in opioid-naive patients and when used in higher doses or with other CNS depressants. Risk of accidental exposure leading to fatal overdose. Risk of abuse, misuse, addiction, and diversion. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected paralytic ileus. Use only in opioid-tolerant patients for outpatient chronic pain management.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression: monitor closely, especially during initiation and dose titration. Abuse and addiction potential: fentanyl is a Schedule II controlled substance. Life-threatening respiratory depression with concurrent use of benzodiazepines or CNS depressants. Serotonin syndrome when coadministered with serotonergic drugs. Adrenal insufficiency. Severe hypotension, including orthostatic hypotension. Risk of seizures in patients with seizure disorders. Avoid use in patients with head injury or increased intracranial pressure. Biliary tract spasm. Use in pregnancy may cause neonatal opioid withdrawal syndrome. Avoid abrupt discontinuation to prevent withdrawal. Must be used only in opioid-tolerant patients for outpatient management.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to fentanyl or any component of the product, significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, known or suspected gastrointestinal obstruction (including paralytic ileus), concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such therapy.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid or limit alcohol and grapefruit juice as they can potentiate respiratory depression and alter fentanyl metabolism. Maintain adequate hydration and fiber intake to prevent constipation.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal opioid withdrawal syndrome; no structural malformations reported at therapeutic doses.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fentanyl is excreted into breast milk in low concentrations; M/P ratio is approximately 0.4. Limited data suggest minimal risk at maternal doses; however, monitor infant for signs of sedation or respiratory depression. Avoid use with breastfeeding for 24 hours after administration due to long half-life.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustment required for acute pain; however, increased clearance in late pregnancy may necessitate higher doses for chronic pain. Use lowest effective dose for shortest duration to minimize neonatal withdrawal risk.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
FENTANYL-100 transdermal patch is indicated only for opioid-tolerant patients with chronic pain requiring around-the-clock analgesia. Apply to non-irritated, non-hairy skin on upper torso or inner forearm; avoid heating pads, saunas, or sun exposure that increase absorption. Monitor for respiratory depression, especially in opioid-naive patients. Patches should be replaced every 72 hours; do not cut or damage the patch. Dispose of used patches by folding adhesive sides together and flushing down toilet.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply the patch to clean, dry, hairless skin and press firmly for 30 seconds.,Do not expose the patch to direct heat sources (heating pads, hot tubs, electric blankets).,Keep away from children and pets; used patches must be flushed down toilet.,Do not drink alcohol or take other central nervous system depressants without consulting your doctor.,Report any difficulty breathing, extreme drowsiness, or confusion immediately.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-100 vs ABSTRAL, answered by our medical review team.
FENTANYL-100 is a Opioid Agonist that works by Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-100 and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-100 is: 100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENTANYL-100 and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENTANYL-100 is classified as Category D/X. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal . ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.